Adaptimmune    Print Page  |  Close Window

IR Overview

IR Overview

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.


SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP, and NY-ESO are moving through clinical studies in multiple cancer types.

$8.54 Stock is Up 0.04 (0.47%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume94,817
Today's Open$8.55
Previous Close$8.50
Data as of 01/23/18 10:03 a.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
01/08/18Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data from its two ongoing pilot studies of SPEAR T-cells targeting MAGE-A10, one in non-small cell lung cancer (NSCLC) and a triple tumor study in bladder, melanoma, and head & neck cancers. To date, 8 patients have each received 100 million transduced MAGE‑A10 SPEAR T-cells in the first dose coh... 
Printer Friendly Version
01/08/18Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company
Successful Manufacturing of SPEAR T-cells for a Patient at its Navy Yard Site and Agreement with Cell and Gene Therapy Catapult to Increase Vector Manufacturing Capacity PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has successfully manufactured the first SPEAR T-cells for a patient at its Navy Yard facility in Philadelphia. In addition, Adaptimmune anno... 
Printer Friendly Version
01/04/18Paul Stead Joins Adaptimmune as Vice President of Business Development
PHILADELPHIA, Pa. and OXFORD, England, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B. Pharm, PhD, MBA, MR PharmS has joined the Company as Vice President of Business Development. "I am delighted to welcome Paul to Adaptimmune. Paul has a tremendous wealth of business development experience and joins Adaptimmune at a critical inflection point in the Company’s journey, as we are focu... 
Printer Friendly Version
12/11/17Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study
PHILADELPHIA and OXFORD, United Kingdom, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of autologous stem cell transplant (ASCT) presented by the main investigator at the annual ASH meeting. “Mature data from this study in multiple myeloma continues to show promising efficacy and acceptab... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.